EVFM - Evofem birth control product Phexxi shelf life extended by a year

The U.S. FDA has extended the shelf life of Evofem's (NASDAQ:EVFM) Phexxi (lactic acid, citric acid, potassium bitartrate) birth control gel from three to four years. When Phexxi was approved in 2020, its shelf life was 30 months. In April 2022, that was extended to three years. Later this year, Evofem (EVFM) plans a top-line readout of a phase 3 trial of Phexxi to prevent chlamydia and gonorrhea. In May, Evofem (EVFM) shares plunged after announcing a public offering of common shares.

For further details see:

Evofem birth control product Phexxi shelf life extended by a year